A fully integrated, automated and rapid detection system for KRAS mutations

Oncology Reports

Volumn 26, Issue 3, 2011, Pages 609-613

  Ureshino, Norio ^a,b   Sueoka Aragane, Naoko ^a   Nakamura, Tomomi ^a   Sato, Akemi ^a   Komiya, Kazutoshi ^a   Iwanaga, Kentaro ^a,b   Mitsuoka, Masahiro ^a   Takeda, Yuji ^a   Hayashi, Shinichiro ^a   Sueoka, Eisaburo ^c   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Prefectural Hospital Koseikan   (Japan)

^c SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

KRAS mutations; Non small cell lung cancer; Quenching probe

Indexed keywords

K RAS PROTEIN; PLASMID DNA;

ARTICLE; AUTOANALYSIS; CANCER CELL; CONTROLLED STUDY; DATA SYNTHESIS; DIRECT SEQUENCE METHOD; GENE DOSAGE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LUNG ADENOCARCINOMA; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; QUENCHING PROBE METHOD; REACTION TIME; SYSTEM ANALYSIS; WILD TYPE;

ADENOCARCINOMA; AUTOMATION, LABORATORY; CODON; DNA MUTATIONAL ANALYSIS; DNA PROBES; HUMANS; LIMIT OF DETECTION; LUNG NEOPLASMS; MUTATION; NUCLEIC ACID HYBRIDIZATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RHODAMINES;

EID: 79959937823     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1341     Document Type: Article

References (18)

1. Malumbres M and Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465, 2003.
2. Jiang Y, Kimchi ET, Staveley-O'Carroll KF, et al: Assessment of K-ras mutation: a step toward personalized medicine for patients with colorectal cancer. Cancer 115: 3609-3617, 2009.
3. Parsons BL and Meng F: K-RAS mutation in the screening, prognosis and treatment of cancer. Biomark Med 3: 757-769, 2009.
4. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours. Int J Oncol 7: 413-429, 1995.
5. Kosaka T, Yatabe Y, Endoh H, et al: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64: 8919-8923, 2004. (Pubitemid 39665498)
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutation and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
7. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844, 2006. (Pubitemid 43259866)
8. Eberhard DA, Johnson BE, Amler LC, et al: Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909, 2005.
9. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17, 2005.
10. Massarelli E, Varella-Garcia M, Tang X, et al: KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13: 2890-2896, 2007. (Pubitemid 46849563)
11. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
12. Tanaka R, Kuroda J, Stevenson W, et al: Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res 32: 1462-1467, 2008.
13. Suzuki T, Nakagawa T, Endo H, et al: The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer 42: 35-41, 2003. (Pubitemid 37153133)
14. Samowitz WS, Curtin K, Schaffer D, et al: Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193-1197, 2000.
15. Matsumoto N, Kakihara F, Kimura S, et al: Single nucleotide polymorphism genotyping of CYP2C19 using a new automated system. Anal Biochem 370: 121-123, 2007. (Pubitemid 47404484)
16. Sasaki H, Okuda K, Kawano O, et al: Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep 18: 623-628, 2007.
17. Finberg KE, Sequist LV, Joshi VA, et al: Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J Mol Diagn 9: 320-326, 2007. (Pubitemid 47305068)
18. Hata A, Katakami N, Fujita S, et al: Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5: 1197-200, 2010.